- Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Roy, L., Guilhot, J., Krahnke, T., Guerci-Bresler, A., Druker, B.J., Larson, R.A., O'Brien, S., So, C., Massimini, G., Guilhot, F. Blood (2006)